RxDoctor Payments Data

Gary Wallace, MD

Ophthalmology · Idaho Falls, IDNPI 1144335290

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 62.1% of it on its own, with 5 other manufacturers making up the rest. That places this record below the midpoint for ophthalmology clinicians in ID, where the typical reported total is $971.

$614in general payments, 2019–2025

Across 23 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$382
  • Sight Sciences, Inc.$77
  • Johnson & Johnson Surgical Vision, Inc.$75
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$47
  • Bausch & Lomb Americas Inc.$22
  • AbbVie$11

What the payments were for

  • Food & beverage$614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$614 in reported general payments places this provider in the 35th percentile of 60 ophthalmology providers in Idaho.

See all ophthalmology providers in Idaho

Medicare billing

Part B allowed, 2024
$224,039
Medicare patients
746
Services billed
2,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost26$12,187
Prednisolone Acetate304$7,726
Loteprednol Etabonate15$2,713
Ketorolac Tromethamine169$2,675
Latanoprost286$2,432
Ofloxacin145$1,640
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat77$1,463
Travoprost23$1,457
Timolol Maleate74$1,221
Brimonidine Tartrate126$1,058
Fluorometholone16$767
MoxifloxacinMoxifloxacin Hcl13$455
ValacyclovirValacyclovir Hcl14$307
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$217
Dorzolamide Hcl13$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$11$12,18726 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$47$2,71315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 60 ophthalmology providers in Idaho.

Other ophthalmology in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →